{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:44:39Z","timestamp":1756464279952},"reference-count":32,"publisher":"Hindawi Limited","issue":"11","license":[{"start":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T00:00:00Z","timestamp":1284508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T00:00:00Z","timestamp":1284508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1111\/j.1742-1241.2010.02493.x","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T01:55:50Z","timestamp":1284602150000},"page":"1535-1540","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["New once-daily formulation for trospium in overactive bladder"],"prefix":"10.1155","volume":"64","author":[{"given":"C.","family":"Chapple","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2010,9,15]]},"reference":[{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neuourol Urodyn"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2680.2001.00231.x","article-title":"The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro","volume":"21","author":"Chess-Williams","year":"2001","journal-title":"J Auton Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ucl.2006.06.006","article-title":"Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder","volume":"33","author":"Staskin","year":"2006","journal-title":"Urol Clin North Am"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/0091270009345498","article-title":"Pharmacokinetics of once-daily trospium chloride 60\u2003mg extended release and twice daily trospium chloride 20\u2003mg in healthy adults","volume":"50","author":"Silver","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB7|cit7","unstructured":"Sandage B Najarian N Lasseter K The effect of hepatic disease on the pharmacokinetics of trospium chloride. Poster Presentation ICS and IUGA Joint Meeting Paris 2004"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB8|cit8","unstructured":"http:\/\/www.medicines.org.uk\/EMC\/medicine\/22236\/SPC\/Regurin+XL+60mg\/"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB9|cit9","first-page":"984","article-title":"Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data","volume":"36","author":"Schladitz-Keil","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","article-title":"Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients","volume":"53","author":"Kay","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","article-title":"Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin","volume":"62","author":"Kay","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","article-title":"Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers","volume":"47","author":"Pietzko","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB14|cit14","first-page":"217","article-title":"General and traffic safety and the effects of incontinence medication: new studies on the safety potential of urological anticholinergics","volume":"50","author":"Herberg","year":"1999","journal-title":"Med Welt"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11934-004-0064-0","article-title":"Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder","volume":"5","author":"Staskin","year":"2004","journal-title":"Curr Urol Rep"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.juro.2007.05.058","article-title":"Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase three trial","volume":"178","author":"Staskin","year":"2007","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urology.2007.11.008","article-title":"Trospium 60\u2003mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study","volume":"71","author":"Dmochowski","year":"2008","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","article-title":"Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial","volume":"85","author":"Cardozo","year":"2000","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1742-1241.2009.02065.x","article-title":"Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release","volume":"63","author":"Staskin","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1464-410X.2003.04271.x","article-title":"The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women","volume":"92","author":"Dallosso","year":"2003","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1079\/PHN2004627","article-title":"The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men","volume":"7","author":"Dallosso","year":"2004","journal-title":"Public Health Nutr"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2010.02.1239","article-title":"Sanctura XR a muscarinic antagonist resists transport (SMART) across the blood-brain barrier (BBB): a prospective, neurocognitive, biodistribution and pharmacokinetic study of extended release trospium chloride (TrCl)","volume":"183","author":"Staskin","year":"2010","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(02)00177-X","article-title":"Long term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder","volume":"41","author":"Kreder","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1464-410X.2006.06439.x","article-title":"Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study","volume":"98","author":"Haab","year":"2006","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB30|cit30","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shay","year":"2005","journal-title":"Am J Managed Care"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-008-0600-9","article-title":"Persistence with antimuscarinic drug use","volume":"65","author":"Brostrom","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2010.02493.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1464-410X.2005.05913.x","article-title":"Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity","volume":"97","author":"Kim","year":"2005","journal-title":"BJU int"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2010.02493.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2010.02493.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2010.02493.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:55Z","timestamp":1643349895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2010.02493.x"}},"subtitle":["Once daily trospium for overactive bladder"],"short-title":[],"issued":{"date-parts":[[2010,9,15]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02493.x","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,15]]}}}